Percheron Therapeutics — Phase II visibility drives valuation upgrade
We have refreshed our investment case for Percheron as the company heads into CY26 with a clearly defined Phase II plan for HMBD-002, backed by...
232 Views
Percheron Therapeutics — Phase II visibility drives valuation upgrade
We have refreshed our investment case for Percheron as the company heads into CY26 with a clearly defined Phase II plan for HMBD-002, backed by...
222 Views
Percheron Therapeutics — Positive Phase I readout strengthens outlook
Percheron Therapeutics has reported final results from the Phase I dose escalation study of HMBD-002, its monoclonal antibody targeting VISTA, a...
230 Views
Percheron Therapeutics — Resetting the narrative with a VISTA focus
Percheron Therapeutics is an emerging immuno-oncology-focused biotech with a business case anchored on its recent in-licensing of HMBD-002, a Phase...
252 Views
Percheron Therapeutics (PER) - Recruitment Accelerated - Data Readout Likely Q1 CY25
PER announced that 34 out of a total target of 45 patients have commenced treatment in its randomised Phase IIb trial of lead drug ATL1102
255 Views